for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover   PharmAsia News
  [0 followers]  Follow
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [16 journals]
  • Malaria The Main Focus Of New GHIT Fund Allocations
    • Abstract: Japan's GHIT Fund is making new investments in a slew of pipeline projects for malaria, tuberculosis, leishmaniasis and dengue that involve local pharma industry and other academic partners.
      PubDate: Wed, 18 Nov 2015 20:15:01 -050
  • OPINION: Impact Of The TPP On The Pharma Industry
    • Abstract: The final text of the Trans-Pacific Partnership confirms beyond doubt the apprehensions expressed by civil society, academia and the generic industry about new barriers to access to medicines. The TPP has done away with several flexibilities provided under the TRIPS Agreement and the Doha Declaration on Public Health.
      PubDate: Wed, 18 Nov 2015 20:00:00 -050
  • INTERVIEW: ViroMed Seeks Partnerships With Active Role
    • Abstract: South Korea’s ViroMed, a front runner in gene therapy involving naked plasmid DNA, is searching for global partners for its leading project VM202 but is apparently in no hurry to make a decision. In an exclusive interview, its founder and chief science officer tells PharmAsia News what sort of partnerships it is seeking and the goals it hopes to achieve in the coming years.
      PubDate: Wed, 18 Nov 2015 19:25:01 -050
  • Stakeholders Urge Major Changes To PBS Listing Guidelines
    • Abstract: The future shape of Australia's system for listing medicines on the Pharmaceutical Benefits Scheme is becoming clearer after the government published stakeholder responses to a consultation on the long-awaited review of the Pharmaceutical Benefits Advisory Committee guidelines, which are used by the pharmaceutical industry to prepare requests for PBS listing.
      PubDate: Tue, 17 Nov 2015 23:45:01 -050
  • GeneOne Links With WRAIR For First MERS Vaccine Trial
    • Abstract: South Korea's GeneOne Life continues to make progress in the development of the world's first DNA vaccine for Middle East Respiratory Syndrome (MERS). After filing an IND with the US FDA last month for a Phase I study, it has now signed an agreement with the Walter Reed Army Institute of Research to jointly proceed with the trial at the US institute.
      PubDate: Tue, 17 Nov 2015 20:35:01 -050
  • India Plans To Sell Generic Cancer, CV Drugs At Hefty Discounts
    • Abstract: India has announced a pilot scheme to sell hundreds of generic cancer and cardiovascular drugs, as well as cardiac implants, at levels at least 50% below normal retail prices through government-run outlets, in a drive to make important medicines more affordable to its vast population.
      PubDate: Tue, 17 Nov 2015 19:15:01 -050
  • Turkey Company Roundup: New Cancer R&D Center, AZ Collaboration
    • Abstract: Onko-Kocsel Pharmaceutical has opened a new oncology R&D facility, while AstraZeneca and Koc University are intensifying their research collaboration for prostate cancer. GSK has appointed a respected academician as a scientific advisor for developing countries and Alcon has named a new regional general manager for Turkey and Azerbaijan.
      PubDate: Tue, 17 Nov 2015 01:10:00 -050
  • NDAs Face Rejection As China FDA Starts ‘Intensive Review’
    • Abstract: In a rare move, the China FDA has rejected 11 new drug applications from eight companies that were in its review queue, signaling more action to come as the agency ups punishments for clinical data forgery and prepares another intensive review campaign, its third in a decade.
      PubDate: Tue, 17 Nov 2015 00:10:02 -050
  • Results Roundup: Commitment Undimmed By Mixed Emerging Markets
    • Abstract: The last quarter provided a decidedly varied set of results for multinational pharma firms active in Asian and other developing markets, with some adjusting to shifting conditions in leading market China better than others, while pricing pressures and rising competition took a toll on some. Meanwhile at major Indian firms, acquisitions were both helping and hampering the performance of top companies.
      PubDate: Mon, 16 Nov 2015 21:40:01 -050
  • New Samsung Biosimilar Results Bode Well For Portfolio
    • Abstract: With its first biosimilar product set to be launched by the end of this year, Samsung Bioepis has presented new long-term results from Phase III trials for several of its autoimmune disease biosimilars that show comparable safety and efficacy to the original products.
      PubDate: Mon, 16 Nov 2015 20:10:00 -050
  • MNCs Bolstering China Presence Despite Slowdown
    • Abstract: Despite a general economic and pharma market slowdown in China, several pharmaceutical multinationals have recently unveiled a slew of investments to expand their presence and secure sustainable growth in the country, where the underlying factors for the health care sector are seen remaining strong.
      PubDate: Mon, 16 Nov 2015 01:25:01 -050
  • Hospital Drug Spending Declining In China: Health Yearbook
    • Abstract: Despite demand for health services remaining strong amid an economic slowdown in China, drug expenditure is declining in both large hospitals and community clinics, adding another concern to an already fragile pharma sector.
      PubDate: Sun, 15 Nov 2015 21:10:01 -050
  • To The East! Leo CEO On Astellas Deal And Global Ambitions
    • Abstract: The acquisition of Astellas's dermatology business for €675m ($725m) by Denmark's skin disease specialist Leo Pharma, announced Nov. 11, is as much about satisfying the company's desire to reach critical mass in certain markets, including China, as it is about reviving an aging portfolio of products.
      PubDate: Sun, 15 Nov 2015 19:55:00 -050
  • WTO Exemptions To Give Leg-Up To Bangladeshi, Indian Firms'
    • Abstract: The WTO Council's recent decision to grant least-developed country members an exemption from implementing intellectual property provisions, such as patents, on medicines is expected to give Bangladesh's up-and-coming pharma industry valuable buffer time to catch up with and possibly take on rivals in the region.
      PubDate: Thu, 12 Nov 2015 23:20:00 -050
  • New WuXi/Lilly Deal Builds On Long Partnership
    • Abstract: WuXi and Lilly are building on a long history of collaboration by entering into a new partnership for the development in China of an experimental drug that addresses cardiovascular risk in patients with dyslipidemia, a huge unmet medical need in the country. The move also marks another step in WuXi’s flexible approach to international alliances.
      PubDate: Thu, 12 Nov 2015 20:45:00 -050
  • Celltrion Files First Rituximab Biosimilar In Europe
    • Abstract: Following the launch of its biosimilar version of Remicade, South Korea’s Celltrion has applied for European approval of its second biosimilar candidate, rituximab, marking the first filing in Europe for a biosimilar of the CD20-targeted oncology antibody.
      PubDate: Thu, 12 Nov 2015 19:55:00 -050
  • Strong Q2 For Cipla Amid Waning Generic Nexium Impact
    • Abstract: Cipla has reported robust growth in the second quarter, buoyed by one-off revenues from the US, but the Indian company sought to temper full-year top-line expectations in view of the strong first-half showing.
      PubDate: Thu, 12 Nov 2015 00:55:02 -050
  • China Reforms Welcome, But More Needed: Frazier
    • Abstract: Visiting Beijing on another grey day chocked with thick smog, PhRMA chairman Kenneth Frazier stressed the need for drug companies to adopt flexible pricing practices in the Chinese market, along with reimbursement and other measures to support innovation, and a globally-harmonized, science-based, transparent and predictable regulatory framework.
      PubDate: Thu, 12 Nov 2015 00:35:01 -050
  • Astellas Offloads Ailing Derma Business To LEO
    • Abstract: In its second major transaction this week, Astellas is to divest its declining global dermatology business to sector specialist Leo for around $727m, in a move that enables the Japanese firm to focus on its core therapy areas.
      PubDate: Wed, 11 Nov 2015 21:00:01 -050
  • Amgen Sets Up For Independence In Korea
    • Abstract: In a sign South Korea is becoming an increasingly important market for multinational biopharma firms, Amgen has set up an independent affiliate in the country. The US biotech giant plans to bring more clinical trials and innovative therapies for serious diseases to a country that it sees as offering medical excellence and a large and diverse patient population.
      PubDate: Wed, 11 Nov 2015 20:05:01 -050
  • What Lies Ahead For China’s Newest Health Care Initiative'
    • Abstract: Amid the challenges of rising health care costs and an aging population, a new focus on primary care and disease prevention signals a new direction for Chinese healthcare reforms, as the government touts a “Health China” initiative under its new mid-term economic plan.
      PubDate: Tue, 10 Nov 2015 22:45:01 -050
  • Turkey Regulatory Update: Pharma Black Market Worries
    • Abstract: Black market activities in Turkey are increasing for some expensive cancer drugs that are not usually available on the local market, while 12,000 people have received certificates to work in the medical technology sector. Meanwhile, the country is pursuing robotic surgery advances and the SGK has added 13 generic drugs to the national reimbursement list.
      PubDate: Tue, 10 Nov 2015 20:55:02 -050
  • Challenges Linger as Chinese Firms Kick Off R&D Race (Pt.2)
    • Abstract: China’s pharmaceutical industry is entering a critical period of transformation as it is losing its traditional price competitiveness in the international market and is now looking more to develop its potential as a force in original R&D. New development models and innovative firms have emerged in the country in recent years, some of which shared their strategies and challenges at a recent meeting in Shanghai.
      PubDate: Tue, 10 Nov 2015 20:05:05 -050
  • Astellas Jump-Starts Ophthalmology Ambitions With Ocata Buy
    • Abstract: Astellas's planned $379m purchase of US regenerative medicine venture Ocata will give the Japanese firm a new presence in ophthalmology and strengthen its cell therapy capabilities.
      PubDate: Tue, 10 Nov 2015 01:05:01 -050
  • Violations Uncovered At GSK, Pfizer Chinese Plants
    • Abstract: Both GSK and Pfizer recently have to face challenges from regulatory authorities back home for problems discovered at their manufacturing facilities in China. The two companies said they took the issues seriously working on resolving them.
      PubDate: Mon, 09 Nov 2015 21:40:01 -050
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015